Korro discloses Novo Nordisk termination notice for paused RNA-editing collaboration
Regulatory / securities filing · Korro Bio SEC Form 8-K
Source published: · Event / reporting date: 2026-11-03
Site published: 2026-11-07 · Updated: 2026-11-07
This source is linked automatically. Choose a question to get started.
What changed
Korro disclosed that Novo Nordisk gave termination notice on November 3 for their research and license agreement, effective February 1, 2027. The collaboration had been paused since November 2025. Korro received a $10 million upfront payment and research-cost reimbursements, but earned no milestones. The notice concerns this specific agreement rather than all of Korro's RNA-editing programs.
Why it may matter
Potential business implication: partnership termination distinguishes realized payments from contingent deal values and highlights collaboration risk without establishing platform-wide technical failure.
The interpretation above is analysis, not a conclusion attributed to the original source.
Read the original source ↗Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections